Merck KGaA sells off its biosimilars portfolio in €670M deal; uniQure boosted by PRIME; Struggling Ophthotech gets new CEO
→ With its new approval for the checkpoint drug avelumab in the bank, so to speak, Merck KGaA has completed a deal to sell …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
